Immune checkpoint inhibitors have significantly transformed cancer care in the past decade, with the approval of the first CTLA-4 inhibitor in 2011 and the PD-1/PD-L1 inhibitors. However, many patients do not respond to the drug or become resistant after some time. Therefore, pharmaceutical companies have focused on developing next-generation immune checkpoint inhibitors that target new pathways like LAG-3, TIGIT, TIM-3, VISTA, PVRIG, BTLA, and ILT4. As of 2026, only one next-generation immune checkpoint inhibitor targeting a novel checkpoint pathway has achieved global regulatory approval: Opdualag (nivolumab + relatlimab), developed by Bristol Myers Squibb. Opdualag: Establishing the First Commercial Benchmark Approved by the US FDA on March 18, 2022, and further approved by European Commission in September 2022, Opdualag combines nivolumab (anti-PD-1) with relatlimab (anti-LAG-3) in a fixed-dose intravenous formulation for first-line treatment of unresectable or metastatic melanoma. Relatlimab is the first approved LAG-3 inhibitor, making Opdualag the first therapy to introduce a novel checkpoint target beyond PD-1, PD-L1, and CTLA-4 into routine oncology practice. Sales of Opdualag (Relatlimab), 2022–2025 Global revenue increased nearly 4.7-fold between 2022 and 2025, reflecting strong physician adoption and increasing penetration in melanoma treatment. The U.S. continues to account for approximately 88% of total revenue, while international markets are contributing an increasing share following broader regulatory approvals and market launches. Opdualag Revenue Growth, 2022–2025 The commercial trajectory demonstrates that even with a single approved indication, next-generation checkpoint inhibition has already established a billion-dollar market opportunity. Current Development Strategy: Expanding Beyond Melanoma Bristol Myers Squibb is actively pursuing lifecycle expansion for Opdualag across additional solid tumors. According to the company's current development pipeline, the major ongoing opportunities include: Nivolumab + Relatlimab (high-dose formulation) is being evaluated in Phase III trials for first-line PD-L1 ≥1% non-small cell lung cancer (NSCLC), representing the largest near-term expansion opportunity for Opdualag due to the significant patient population and high unmet need in this market. Next-generation Checkpoint Inhibitors: Pipeline Products Company Novel Checkpoint Development Phase Gilead Sciences/Arcus TIGIT Phase III Novartis TIM3 Phase II/III Compugen PVRIG Phase II Hummingbird Bioscience VISTA Phase I/II The next-generation checkpoint inhibitor market remains at an early stage, with Opdualag currently leading the space. The next-generation checkpoint inhibitor market is expected to expand as new immune targets progress through clinical development. Share this article